CDTX - Cidara Therapeutics, Inc.
Chart Events
Momentum
Performance Outlook
- Short Term2W - 6W
- Mid Term6W - 9M
- Long Term9M+
| Previous Close | 3.6600 |
| Open | 3.7200 |
| Bid | 3.6700 x 1300 |
| Ask | 4.2200 x 1200 |
| Day's Range | 3.6400 - 3.8100 |
| 52 Week Range | 1.2230 - 4.4500 |
| Volume | 172,810 |
| Avg. Volume | 309,773 |
| Market Cap | 150.896M |
| Beta (5Y Monthly) | 1.91 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.3310 |
| Earnings Date | May 13, 2020 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 6.61 |
Fair Value
Related Research
- GlobeNewswire
Cidara Therapeutics Added to Russell 3000® Index
Cidara Therapeutics, Inc. (CDTX), a biotechnology company developing long-acting therapeutics to transform the standard of care for patients facing serious fungal or viral infections, today announced that it has been added to the Russell 3000® Index at the conclusion of the Russell indexes annual reconstitution, effective upon the U.S. market open today, June 29, 2020. Russell indexes are widely used by investment managers and institutional investors for index funds and as benchmarks for active investment strategies. Russell indexes are part of FTSE Russell, a leading global index provider.
- GlobeNewswire
Cidara Therapeutics to Participate in Cantor Fitzgerald Virtual Symposium: Winning Ways to Treat Infections and COVID-19
Cidara Therapeutics, Inc. (CDTX), a biotechnology company developing long-acting therapeutics to transform the standard of care for patients facing serious fungal or viral infections, today announced that Jeffrey Stein, Ph.D., President and Chief Executive Officer, will participate in the Cantor Fitzgerald “Winning Ways to Treat Infections and COVID-19” Virtual Symposium on Tuesday, June 30, 2020. The discussion is intended to provide important updates on how innovative companies, such as Cidara, are leveraging their proprietary technology platforms to develop new ways to treat infections, including COVID diseases. The panelists will also discuss how COVID-19 underscores the need for stockpiling in the U.S. The call will be moderated by Louise Chen, Senior Research Analyst and Managing Director of Cantor Fitzgerald.
- GlobeNewswire
Cidara Therapeutics to Present at the Raymond James Human Health Innovations Conference
SAN DIEGO, June 11, 2020 -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics to transform the standard of care for patients.
- Simply Wall St.
Cidara Therapeutics, Inc. (NASDAQ:CDTX) Insiders Increased Their Holdings
We often see insiders buying up shares in companies that perform well over the long term. The flip side of that is...
- GlobeNewswire
Cidara Therapeutics Doses First Patient in Pivotal Phase 3 ReSPECT Trial of Rezafungin for Prevention of Invasive Fungal Disease in Patients Undergoing Allogeneic Blood and Marrow Transplantation
Cidara Therapeutics, Inc. (CDTX), a biotechnology company developing long-acting therapeutics to transform the standard of care for patients facing serious fungal or viral infections, and Mundipharma today announced that the first patient has been dosed in its ReSPECT pivotal Phase 3 clinical trial evaluating the efficacy and safety of the company’s lead antifungal candidate, rezafungin, for the prevention of invasive fungal disease in patients undergoing allogeneic blood and marrow transplantation (BMT). Rezafungin is a novel, once-weekly echinocandin being developed for both the treatment and prevention of severe fungal infections.
- Zacks
Cidara Therapeutics (CDTX) Reports Q1 Loss, Misses Revenue Estimates
Cidara Therapeutics (CDTX) delivered earnings and revenue surprises of -35.29% and -49.40%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
- GlobeNewswire
Cidara Provides Corporate Update and Reports First Quarter 2020 Financial Results
SAN DIEGO, May 13, 2020 -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics to transform the standard of care for patients.
- GlobeNewswire
Cidara Therapeutics Announces New Clinical and Preclinical Data for Rezafungin and Influenza AVCs from the European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)
Cidara Therapeutics, Inc. (CDTX), a biotechnology company developing long-acting therapeutics to transform the standard of care for patients facing serious fungal or viral infections, today announced the publication of 10 abstracts reporting new clinical and preclinical data on the Company’s antifungal rezafungin program and preclinical data on its Cloudbreak® antiviral program. The abstracts are being published by the European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) in an online book of abstracts that had been accepted for presentations at ECCMID 2020, which was canceled due to the coronavirus global pandemic.
- Zacks
What Makes Cidara Therapeutics (CDTX) a New Strong Buy Stock
Cidara Therapeutics (CDTX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank 1 (Strong Buy).
- GlobeNewswire
Cidara Therapeutics to Participate in Antifungal and COVID-19 Therapeutics Panels at Maxim Group’s Infectious Disease Virtual Conference
SAN DIEGO, April 28, 2020 -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a clinical-stage biotechnology company focused on the discovery, development and commercialization of.
- GlobeNewswire
Cidara Therapeutics to Present at the 19th Annual Needham Virtual Healthcare Conference
SAN DIEGO, April 07, 2020 -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a clinical-stage biotechnology company focused on the discovery, development and commercialization of.
- GlobeNewswire
Cidara Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2019 Financial Results
SAN DIEGO, March 04, 2020 -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a clinical-stage biotechnology company focused on the discovery, development and commercialization of.
- GlobeNewswire
Cidara Therapeutics to Present at Transplantation & Cellular Therapy (TCT) and Mycology 2020 Medical Conferences
SAN DIEGO, Feb. 18, 2020 -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing therapeutics to improve the standard of care for patients facing severe.
- GlobeNewswire
Cidara Therapeutics Announces Closing of Rights Offering
SAN DIEGO, Feb. 12, 2020 -- Cidara Therapeutics, Inc. (Nasdaq: CDTX) (“Cidara”) today announced the closing of its previously announced rights offering (the “Rights Offering”)..
- Simply Wall St.
Some Cidara Therapeutics (NASDAQ:CDTX) Shareholders Have Taken A Painful 74% Share Price Drop
While not a mind-blowing move, it is good to see that the Cidara Therapeutics, Inc. (NASDAQ:CDTX) share price has...
- GlobeNewswire
Cidara Therapeutics Announces Commencement of Rights Offering
Under the terms of the Rights Offering, the holders, as of 5:00 p.m., New York time, on January 21, 2020, of Cidara’s common stock and Series X convertible preferred stock, and Cidara’s warrants issued on May 21, 2018, are entitled to purchase up to 11,952,191 shares of common stock in the aggregate at a subscription price equal to $2.51 per share, or under certain circumstances, shares of non-voting Series X convertible preferred stock in lieu of common stock (collectively, the “Offered Shares”), as more fully described in the prospectus supplement, dated January 22, 2020, relating to the Rights Offering.
- Zacks
New Strong Sell Stocks for January 16th
Here are 5 stocks added to the Zacks Rank 5 (Strong Sell) List today
- GlobeNewswire
Cidara Therapeutics Announces Proposed Rights Offering
Under the terms of the rights offering, investors as of January 21, 2020 in Cidara’s common stock and preferred stock, as well as the holders of Cidara’s warrants issued on May 21, 2018, will receive a subscription right entitling them to purchase their pro rata share of the $30.0 million offering amount. The rights offering will be fully backstopped by BVF Partners L.P. and Stonepine Capital, LP, each of which have agreed to purchase, at a minimum, its respective as-converted pro rata share of the offering amount, plus an additional amount of securities that are not subscribed for by other purchasers in the rights offering, for a total of up to $30.0 million.
- Insider Monkey
Hedge Funds Bailed Out Of Cidara Therapeutics Inc (CDTX) Too Early
Does Cidara Therapeutics Inc (NASDAQ:CDTX) represent a good buying opportunity at the moment? Let’s quickly check the hedge fund interest towards the company. Hedge fund firms constantly search out bright intellectuals and highly-experienced employees and throw away millions of dollars on satellite photos and other research activities, so it is no wonder why they tend […]
- Simply Wall St.
Should You Take Comfort From Insider Transactions At Cidara Therapeutics, Inc. (NASDAQ:CDTX)?
We often see insiders buying up shares in companies that perform well over the long term. Unfortunately, there are...
- GlobeNewswire
Cidara Therapeutics to Present at Two Upcoming Medical Conferences
SAN DIEGO, Dec. 03, 2019 -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced that.
- GlobeNewswire
Cidara Therapeutics Named a San Diego Metro Area Top Workplace for the Third Consecutive Year
Cidara Therapeutics, Inc. (CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced that it has been named a Top Workplace by The San Diego Union-Tribune for the third consecutive year. Cidara was the top life sciences company and only biotech included in the small company category in the San Diego Metro Area. “It is a great honor to be named as one of the best places to work in the San Diego Metro Area for the third consecutive year,” said Jeffrey Stein, Ph.D., president and chief executive officer of Cidara.
- GlobeNewswire
Cidara Provides Corporate Update and Reports Third Quarter 2019 Financial Results
SAN DIEGO, Nov. 07, 2019 -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today reported.
- GlobeNewswire
Cidara Therapeutics Hosting Key Opinion Leader Meeting on Rezafungin and Cloudbreak Programs
Cidara Therapeutics, Inc. (CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced that it will host a Key Opinion Leader (KOL) meeting on its rezafungin and Cloudbreak programs on November 14 in New York City for institutional investors, sell-side analysts, and business development professionals. The meeting will feature presentations from Key Opinion Leaders, Neil J. Clancy, M.D. (University of Pittsburgh), Kieren Marr, M.D. (Johns Hopkins University School of Medicine), and Allison McGeer, M.D. (University of Toronto), who will discuss the unmet medical need in the treatment and prevention of fungal and viral diseases.
- GuruFocus.com
Weekly CFO Buys Highlight
Insiders invested in VBI Vaccines, Cidara Therapeutics and Ocugen Continue reading...
